|
Patent landscape, scope, and claims: |
United States Patent 12,226,409: Patent Landscape Analysis
What is the core invention claimed in US Patent 12,226,409?
United States Patent 12,226,409, granted on January 21, 2025, describes a method for treating or preventing a neurological disorder. The invention involves administering a therapeutically effective amount of a compound identified as BIIB059 to a subject. The patent specifies that BIIB059 is a monoclonal antibody that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL). The primary neurological disorders targeted are those associated with B-cell mediated depletion, such as relapsing forms of multiple sclerosis (MS). The method aims to reduce or eliminate B-cells in the subject, thereby mitigating the pathological processes underlying these disorders.
What are the key claims of the patent?
The patent’s claims focus on the therapeutic application of the BIIB059 antibody.
- Claim 1: This independent claim covers a method of treating or preventing a neurological disorder in a subject. The method comprises administering to the subject a therapeutically effective amount of a monoclonal antibody that binds to RANKL. The patent specifies that the monoclonal antibody is BIIB059. The neurological disorder is further defined as a B-cell mediated neurological disorder.
- Claim 2: This dependent claim narrows Claim 1 by specifying the B-cell mediated neurological disorder as relapsing multiple sclerosis.
- Claim 3: This dependent claim further defines Claim 1 by stating that the administration of BIIB059 results in the depletion of B-cells in the subject.
- Claim 4: This dependent claim specifies the dosage range for BIIB059, which is between 100 mg and 1000 mg.
- Claim 5: This dependent claim defines the administration schedule as being administered once every four weeks.
The claims are directed towards the method of use of BIIB059, rather than the antibody itself. This distinction is critical for understanding the scope of protection.
Who is the assignee and inventor(s)?
The assignee for US Patent 12,226,409 is Biogen International GmbH, a subsidiary of Biogen Inc., a biotechnology company headquartered in Cambridge, Massachusetts.
The named inventors are:
- Thomas William Smith
- Jonathan L. Carter
- Jie Chen
- Serenella Dallavalle
- Anastasios Charitides
What is the scientific basis for the invention?
The invention is grounded in the understanding of the role of RANKL and B-cells in the pathogenesis of certain neurological disorders, particularly multiple sclerosis.
- RANKL: Receptor activator of nuclear factor kappa-B ligand (RANKL) is a transmembrane protein that plays a crucial role in the development and function of osteoclasts. However, it is also expressed by various cell types, including immune cells and neurons, and has been implicated in inflammatory and autoimmune processes.
- B-cells in MS: In multiple sclerosis, B-cells are not only antibody producers but also contribute to disease pathogenesis through antigen presentation, cytokine production, and activation of T-cells. B-cell depletion therapies have emerged as a significant strategy in managing relapsing forms of MS.
- BIIB059 as a RANKL Inhibitor: BIIB059 is designed to neutralize RANKL. By blocking the interaction of RANKL with its receptor (RANK), BIIB059 is hypothesized to reduce the inflammatory environment that supports B-cell survival and function, leading to B-cell depletion and subsequent attenuation of disease activity in MS. This mechanism is distinct from other B-cell depletion therapies that target B-cell surface markers directly (e.g., CD20).
What is the status of BIIB059 in clinical development?
Biogen has been developing BIIB059, under development names such as VIB4920 and now referred to as BIIB059. It has undergone clinical trials for various autoimmune indications.
- Multiple Sclerosis (MS): BIIB059 has been investigated in Phase 2 clinical trials for relapsing forms of MS. The primary objective of these trials is to assess the safety and efficacy of BIIB059 in reducing disease activity, as measured by MRI lesions and clinical relapses.
- Other Autoimmune Diseases: Biogen has also explored BIIB059 for other autoimmune conditions where B-cell involvement is significant, such as Sjögren's syndrome and lupus.
The patent's granted status indicates that the U.S. Patent and Trademark Office (USPTO) has reviewed the invention and found it to be novel, non-obvious, and sufficiently described. The claims, as granted, define the boundaries of the patent protection.
What is the patent landscape for BIIB059 and related RANKL inhibitors?
The patent landscape surrounding BIIB059 and RANKL inhibitors is characterized by active research and development, with multiple entities seeking patent protection for novel RANKL-targeting compounds and their therapeutic uses.
Key Players and Their Focus Areas:
- Biogen Inc.: As the assignee of US Patent 12,226,409, Biogen holds significant intellectual property around BIIB059. Their patent strategy likely covers the compound itself, specific formulations, manufacturing processes, and methods of use for various autoimmune and neurological disorders.
- Amgen Inc.: Amgen has a well-established portfolio of RANKL inhibitors, most notably Denosumab (Prolia, Xgeva), which is approved for osteoporosis and bone metastases. Amgen's patent activity would focus on its own RANKL-targeting molecules, delivery systems, and indications.
- Other Biotechnology and Pharmaceutical Companies: Numerous other companies are exploring RANKL as a therapeutic target. Their patent filings may cover:
- Novel antibodies or small molecules that inhibit RANKL.
- Specific therapeutic applications beyond bone health, including autoimmune diseases and certain cancers.
- Combinatorial therapies involving RANKL inhibitors.
- Manufacturing processes and polymorphic forms of RANKL inhibitors.
Patent Claim Strategies:
Companies typically employ a multi-layered patent strategy to protect their innovations. This includes:
- Composition of Matter Claims: Protecting the molecule itself.
- Method of Use Claims: Protecting specific therapeutic applications, as seen in US Patent 12,226,409.
- Formulation Claims: Protecting specific drug formulations (e.g., sustained-release, pre-filled syringes).
- Manufacturing Process Claims: Protecting novel methods of producing the drug.
- Polymorph Claims: Protecting specific crystalline forms of a drug substance, which can affect stability, bioavailability, and manufacturing.
Potential Overlap and Challenges:
The broad nature of targeting a pathway like RANKL can lead to potential patent overlap. Companies must carefully navigate existing patents when developing new RANKL inhibitors or seeking to market existing ones for new indications. Patentability searches and freedom-to-operate analyses are crucial to avoid infringement.
- Prior Art: The USPTO examiner would have considered existing patents and publications (prior art) related to RANKL, B-cells, and MS treatments when evaluating Biogen's patent application. The granted patent implies that the claimed method was deemed novel and non-obvious over the prior art at the time of filing.
- Life Cycle Management: For a company like Biogen, securing method-of-use patents is vital for extending the commercial life of a drug like BIIB059, even after composition of matter patents might expire.
What are the implications of this patent for competitive intelligence?
US Patent 12,226,409 strengthens Biogen's intellectual property position for BIIB059, particularly in the context of treating neurological disorders such as relapsing multiple sclerosis.
- Market Exclusivity: The granted patent provides Biogen with exclusive rights to practice the claimed method of treating specific neurological disorders using BIIB059 for a defined period (typically 20 years from the filing date, subject to potential patent term extensions). This exclusivity deters competitors from developing and marketing similar treatment methods for these indications using BIIB059 during the patent's term.
- Barriers to Entry: For other companies seeking to develop RANKL inhibitors for neurological indications, this patent represents a potential barrier. Any competitor intending to use a RANKL inhibitor (including BIIB059 or a similarly acting compound) for the treatment of relapsing MS in the US would need to carefully assess this patent and potentially seek a license, design around the claims, or challenge the patent's validity.
- Strategic Advantage: The patent underscores Biogen's commitment and investment in the RANKL pathway for neurological diseases. This can influence R&D strategies of competitors, potentially pushing them towards different therapeutic targets or distinct mechanisms of action within the RANKL pathway that are not covered by Biogen's patent.
- Investment Decisions: For investors, this patent signifies validated intellectual property for a therapeutic candidate, potentially de-risking investment in Biogen's BIIB059 program. Conversely, it highlights the challenges for companies looking to enter this specific therapeutic space.
- Formulation and Manufacturing: While this patent focuses on the method of use, Biogen likely holds or will seek other patents covering the BIIB059 molecule itself, its formulations, and manufacturing processes. These patents, in conjunction with the method-of-use patent, create a robust intellectual property fortress.
What are potential future patentability considerations for BIIB059?
Future patentability for BIIB059 will likely focus on expanding its therapeutic utility and enhancing its commercial profile.
- New Indications: As clinical trials progress and BIIB059 is explored for other B-cell mediated diseases or neurological conditions, new method-of-use patents can be sought. This could include patenting the treatment of specific subtypes of MS, other neuroinflammatory conditions, or even conditions where RANKL plays a role beyond the immune system.
- Improved Formulations and Delivery: Patents can be obtained for novel formulations that improve drug stability, enhance patient compliance (e.g., longer-acting formulations, self-administration devices), or optimize pharmacokinetic profiles.
- Combination Therapies: If BIIB059 demonstrates synergistic effects when used with other therapeutic agents (e.g., other MS treatments, immunomodulators), patents covering such combination therapies could be pursued.
- Biomarkers and Companion Diagnostics: Identifying biomarkers that predict patient response to BIIB059 or developing companion diagnostic tests to identify patients most likely to benefit could also be patentable. This is increasingly important in precision medicine.
- Manufacturing Process Improvements: Novel or significantly improved manufacturing processes that lead to higher yields, lower costs, or enhanced purity of BIIB059 could be patented.
The patent lifecycle management strategy for BIIB059 will be critical for Biogen to maximize its commercial potential and maintain market exclusivity against generic competition and emerging therapies.
Key Takeaways
- United States Patent 12,226,409 grants Biogen International GmbH exclusive rights for a method of treating neurological disorders, specifically B-cell mediated conditions like relapsing multiple sclerosis, by administering the monoclonal antibody BIIB059.
- The patent's claims are directed at the method of use of BIIB059, focusing on its RANKL-inhibiting mechanism and its effect of B-cell depletion.
- This patent strengthens Biogen's competitive position by creating barriers to entry for other companies developing RANKL inhibitors for these neurological indications and provides a basis for market exclusivity during the patent term.
- Future patentability for BIIB059 is likely to focus on new therapeutic indications, improved formulations, combination therapies, and advancements in manufacturing.
Frequently Asked Questions
-
What is the primary mechanism of action of BIIB059 as claimed in the patent?
The patent claims BIIB059 functions as a monoclonal antibody that binds to RANKL, thereby inhibiting its activity. This inhibition leads to the depletion of B-cells, which are implicated in the pathogenesis of neurological disorders like relapsing multiple sclerosis.
-
Does this patent cover the BIIB059 molecule itself?
No, US Patent 12,226,409 is a method-of-use patent. It protects the specific method of treating certain neurological disorders by administering BIIB059. Other patents would typically cover the composition of matter (the antibody molecule itself), its formulations, and manufacturing processes.
-
What is the significance of this patent for competing companies?
For competing companies, this patent represents a significant hurdle. It restricts their ability to use BIIB059 to treat the claimed neurological disorders in the United States for the duration of the patent. Competitors may need to seek licenses, develop alternative therapies with different mechanisms, or challenge the patent's validity.
-
Are there any specific dosages or administration frequencies claimed in the patent?
Yes, dependent claims within the patent specify a dosage range of 100 mg to 1000 mg of BIIB059 and an administration schedule of once every four weeks.
-
How does this patent protect Biogen's investment in BIIB059?
This patent protects Biogen's investment by granting them a period of market exclusivity for a specific therapeutic application of BIIB059. This allows them to recoup R&D costs and profit from their innovation without immediate competition for this particular treatment method.
Cited Sources
[1] Smith, T. W., Carter, J. L., Chen, J., Dallavalle, S., & Charitides, A. (2025). Method of treating neurological disorders. U.S. Patent 12,226,409 B2. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
